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Abstract 
Introduction: Trialing novel cancer therapies in the clinic would benefit from imaging agents that can detect early 
evidence of treatment response. The timing, extent and distribution of cell death in tumors following treatment can 
give an indication of outcome. We describe here an 18F‑labeled derivative of a phosphatidylserine‑binding protein, 
the C2A domain of Synaptotagmin‑I (C2Am), for imaging tumor cell death in vivo using PET.
Methods: A one‑pot, two‑step automated synthesis of N‑(5‑[18F]fluoropentyl)maleimide (60 min synthesis time, 
> 98% radiochemical purity) has been developed, which was used to label the single cysteine residue in C2Am within 
30 min at room temperature. Binding of 18F‑C2Am to apoptotic and necrotic tumor cells was assessed in vitro, and 
also in vivo, by dynamic PET and biodistribution measurements in mice bearing human tumor xenografts treated with 
a TRAILR2 agonist or with conventional chemotherapy. C2Am detection of tumor cell death was validated by correla‑
tion of probe binding with histological markers of cell death in tumor sections obtained immediately after imaging.
Results: 18F‑C2Am showed a favorable biodistribution profile, with predominantly renal clearance and minimal 
retention in spleen, liver, small intestine, bone and kidney, at 2 h following probe administration. 18F‑C2Am generated 
tumor‑to‑muscle (T/m) ratios of 6.1 ± 2.1 and 10.7 ± 2.4 within 2 h of probe administration in colorectal and breast 
tumor models, respectively, following treatment with the TRAILR2 agonist. The levels of cell death (CC3 positivity) fol‑
lowing treatment were 12.9–58.8% and 11.3–79.7% in the breast and colorectal xenografts, respectively. Overall, a 20% 
increase in CC3 positivity generated a one unit increase in the post/pre‑treatment tumor contrast. Significant correla‑
tions were found between tracer uptake post‑treatment, at 2 h post‑probe administration, and histological markers of 
cell death (CC3: Pearson R = 0.733, P = 0.0005; TUNEL: Pearson R = 0.532, P = 0.023).
Conclusion: The rapid clearance of 18F‑C2Am from the blood pool and low kidney retention allowed the spatial dis‑
tribution of cell death in a tumor to be imaged during the course of therapy, providing a rapid assessment of tumor 
treatment response. 18F‑C2Am has the potential to be used in the clinic to assess early treatment response in tumors.
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Introduction
The aim of cancer treatment, whether this is chemo-, 
radio-, targeted- or immuno-therapy [1], is to induce 
tumor cell death, where the two dominant forms of cell 
death are apoptosis and necrosis [2]. Cell death is an 
important and generic target for imaging early treatment 
response [3]. However, despite a long-standing unmet 
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need there are still no reliable techniques for routine 
imaging of cell death in the clinic [4].
Phosphatidylserine (PS) is externalized on the cell sur-
face during apoptosis and is also exposed via the permea-
bilization of the plasma membrane that occurs during 
necrosis. The C2A domain of Synaptotagmin-I binds PS 
in a calcium-dependent manner with nanomolar affinity 
[5, 6]. We have developed a PS-targeted imaging agent 
based on C2A, which was first used in  vivo as a glu-
tathione S-transferase–tagged dimeric construct (GST-
C2A, 84  kDa) for imaging tumor cell death using MRI, 
where the protein was labeled with superparamagnetic 
iron oxide nanoparticles [7] and subsequently with  Gd3+ 
chelates [8]. This GST-tagged construct has also been 
labeled with a 99mTc-chelate for SPECT [9] and with fluo-
rine-18 for PET [10].
Subsequently, we have used the much smaller (16-
kDa) isolated C2A domain [6], which enables better tar-
get access and tissue clearance. Introduction of a single 
cysteine residue, distant from the PS-binding site, using 
site-directed mutagenesis (S78C; C2Am), allowed the 
production of chemically defined derivatives in which 
this single cysteine was labeled with imaging tags. A 
near infrared-labeled derivative showed a fourfold lower 
binding to viable cells in  vitro than a similarly labeled 
Annexin-V and therefore improved specificity for detect-
ing cell death [6]. Annexin-V is another PS-binding pro-
tein, which was tested in the clinic nearly two  decades 
ago in the form of 99mTc-HYNIC-Annexin-V, but showed 
suboptimal pharmacokinetics and extensive non-specific 
binding [11, 12]. A subsequent derivative, 99mTc-rh-
Annexin-V-128, showed a better biodistribution profile 
and targeting of cell death in vivo [13].
We recently evaluated derivatives of C2Am that had 
been labeled for photoacoustic imaging [14] and SPECT 
[15]. The latter were based on 99mTc and 111In chelates 
and could detect tumor cell death in  vivo within 2  h of 
administration, with a tumor-to-muscle contrast of 
~  3. However, they also showed significant renal reten-
tion (> 150% IA/g), which persisted for up to 24  h 
post-administration.
Here, we describe a 18F-labeled derivative of C2Am that 
was tested in human xenograft models of advanced colo-
rectal (Colo205 [16]) and triple-negative breast (MDA-
MB-231 [17]) cancer, treated with either conventional 
chemotherapy or with MEDI3039, which is a multivalent 
tumor necrosis factor (TNF)-related apoptosis-inducing 
ligand receptor-2 (TRAILR2) agonist that can induce 
tumor cell death at picomolar concentrations [18]. We 
analyzed the biodistribution and dosimetry profile of the 
probe and its sensitivity for detecting tumor cell death 
by correlating probe distribution in tumors with histo-
logical markers of tumor cell death in tumor sections. 
Non-specific retention of the probe was evaluated by 
comparing its distribution with that of a site-directed 
mutant, 18F-iC2Am, which is inactive in PS binding [15].
Materials and methods
General
Details of the materials used including the precursor 
N-(5-[18F]fluoropentyl)maleimide and the imaging probe 
18F-C2Am can be found in Additional file 1.
Cell culture
Chemicals were obtained from Sigma-Aldrich unless 
stated otherwise. MDA-MB-231 (ATCC, HTB-26™) and 
Colo205 (ATCC, CCL-222™) were purchased and stably 
transfected with firefly luciferase for bioluminescence 
imaging (BLI) using a method described previously [19], 
and used within ten passages from the original stocks. 
Both cell lines tested negative for mycoplasma and were 
authenticated using short-tandem repeat genetic pro-
filing [20] yielding a 100% match to the cell lines in the 
ATCC database. MDA-MB-231 and Colo205 cells were 
cultured in DMEM or RPMI-1640 medium (Life Tech-
nologies), respectively, supplemented with 2  mmol/L 
l-glutamine and 10% fetal bovine serum (Life Technolo-
gies), in a humidified incubator at 37 °C and 5%  CO2.
Flow cytometry
Colo205 and MDA-MB-231 cells (2 million) were treated 
with 2.5  pM and 10  pM MEDI3039, respectively, for 
24  h, centrifuged (700g, 5  min, 4  °C) and resuspended 
in 100  μL of pre-cooled HBS buffer (HEPES-buffered 
saline: 10 mmol/L HEPES, 150 mmol/L NaCl, 2 mmol/L 
 CaCl2, 1% fetal bovine serum (FBS), pH 7.4). Following 
incubation with SYTOX-Red (Invitrogen, 50  nM) and 
with C2Am-AF750 or AnnexinV-AF647 (conjugated to 
Alexa Fluor 750 or 647, respectively), at concentrations 
of 0.5 μM and 20 nM, respectively, the cells were washed 
twice, resuspended and kept on ice before analysis in 
a Symphony cytometer (Beckman), with 50,000 cells 
counted per event. Data were analyzed using FlowJo soft-
ware (vs. 10) using methods described previously [6].
Cell labeling with 18F‑C2Am
Vehicle- and MEDI3039-treated (10  pM, 24  h) cells 
(n = 3) were harvested, counted and viability assessed 
using a Vi-CELL analyzer (Beckman). The cells were 
then resuspended in HBS buffer and incubated with  [18F]
FPenM-C2Am (1–10 μM, 7–11 MBq, Am = ~ 10.5 GBq/
µmol at the start of labeling) at 37 °C for 20 min. Cell pel-
lets (5 million cells, centrifuged at 700g for 5 min at 4 °C) 
were washed three times with HBS buffer (1  mL) and 
radioactivity counted for 1  min using a gamma counter 
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(AMG Hidex) set to monitor the fluorine-18 gamma 
emission (511 keV).
Animal studies
Animal experiments were performed in compliance with 
a project license issued under the Animals (Scientific 
Procedures) Act of 1986 and were designed with refer-
ence to the UK Co-ordinating Committee on Cancer 
Research guidelines for the welfare of animals in experi-
mental neoplasia [21]. Protocols were approved by the 
Cancer Research UK Cambridge Institute Animal Wel-
fare and Ethical Review Body. Colo205 or MDA-MB-231 
cells (5 or 10 million, respectively) were resuspended in 
0.1  mL PBS or a 1:1 mixture of Matrigel (Corning) and 
complete DMEM, respectively, and implanted subcu-
taneously in the upper back of 10–12  week-old female 
BALB/c Nu/Nu mice (Charles River). Tumors were 
imaged when they reached ~ 1 cm3. For PET/CT imag-
ing, mice were anesthetized using 1–2.5% isoflurane (Iso-
flo, Abbotts Laboratories Ltd.) in a 1:1 mixture of air and 
oxygen (at 1 L/min). MEDI3039, a TRAILR2 agonist, was 
administered at 0.1–0.4  mg/kg (i.v.) [22]. 5-fluorouracil 
(5FU) and doxorubicin (DOX) were used at 50–100 mg/
kg (i.p.) and 100 mg/kg (i.p.), in the Colo205 and MDA-
MB-231 models, respectively.
Production of 18F‑C2Am
A one-pot, two-step automated synthesis (Additional 
file  1: Fig. S1) of the prosthetic group N-(5-[18F]fluoro-
pentyl) maleimide was developed using an automated 
module (GE TracerLab FxFN, 60  min synthesis time, 
> 98% radiochemical purity and 12 ± 3% decay corrected 
yield, n = 3; Additional file  1: Fig. S2). This was used to 
fully label the single cysteine residue in C2Am (Fig.  1) 
within 30 min at 20 °C (Am = 212 ± 30 GBq/µmol, > 95% 
radiochemical purity, n = 3, Fig.  1 and Fig. S3) to give 
18F-C2Am. Details on the radiosynthesis procedure, 
quality control and radiometabolite analysis methods can 
be found in Additional file 1.
Dynamic 18F‑C2Am PET/CT imaging of treatment response
Colo205 (n = 9) and MDA-MB231 (n = 9) tumor–bear-
ing mice underwent bioluminescence imaging (BLI) and 
PET-CT, following injection of 18F-C2Am, which were 
performed in the same 2.5 h imaging session before and 
24  h following treatment with MEDI3039 or chemo-
therapy (5FU or DOX, respectively). Following BLI, heli-
cal CT data were acquired for anatomical reference and 
attenuation correction (isotropic resolution of 0.2  mm). 
PET images, with a nominal isotropic resolution of 
0.6  mm, were reconstructed using a 3D ordered subset 
expectation maximization (OSEM) method in one to 
three coincidence modes, eight iterations and six subsets. 
A 120-min dynamic PET acquisition was initiated 30  s 
prior to intravenous injection of 3.2 ± 1.3 MBq 18F-C2Am 
(150 μg/kg; 10 mL/kg;  SA = 1 MBq/μg), using a nanoScan 
PET/CT (Mediso) scanner. Scans were reconstructed 
into 23 time frames (4 × 15  s, from 0–1 min; 4 × 1 min, 
1–5 min; 11 × 5 min, 5–60 min; 4 × 15 min, 60–120 min). 
Images were normalized and corrected for decay and 
attenuation and analyzed using VivoQuant software (vs. 
3, InviCRO). Three-dimensional tissue regions of interest 
(ROI) were drawn manually, and, if possible, Otsu thresh-
olding was applied to better delineate the ROIs.
Standardized uptake values (SUV) were calculated 
as mean (SUV), median  (SUV50), the 90th percentile 
 (SUV90), peak  (SUVpeak), peak_max  (SUVpeakM) and max-
imum  (SUVmax). SUV (g/mL) was defined as SUV = Cimg/
(IA/BW), where  Cimg is the activity concentration (MBq/
mL) in the ROI, IA is the injected activity (MBq), and 
BW is the body weight of the animal (in grams). The 
pixel with the maximum signal intensity was used to 
calculate  SUVmax. The fraction of injected activity per 
gram of tissue (IA/g, %), the tumor-to-muscle (T/m) and 
Fig. 1 Radiochemical labeling of C2Am, using N‑(5‑[18F]fluoropentyl) maleimide, to yield 18F‑C2Am. The rapid Michael addition reaction takes place 
under mild conditions (20 °C, pH5, HBS buffer) in the presence of ascorbic acid. The secondary structure of C2Am is shown, highlighting the single 
cysteine residue (top, yellow) and the active site (lower) containing three calcium ions (yellow spheres)
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tumor-to-blood (T/b) ratios were also calculated, the lat-
ter two using the lower flank skeletal muscle and carotid 
artery, respectively. Additional details are available in the 
Additional file 1.
Results
Flow cytometry of dying cells using C2Am‑AF750
Following treatment with MEDI3039, MDA-MB-231 and 
Colo205 cells were predominantly necrotic (56.2%) or 
apoptotic (49.6%), respectively (Fig. 2a, b), based on cell 
membrane integrity, determined by Sytox Green staining, 
and the levels of NADH, which have been demonstrated 
previously as independent markers of these two modes 
of cell death [6]. Both cell lines upregulated expression of 
the TRAILR2 receptor upon treatment with the agonist 
(Additional file  1: Fig. S4). Necrotic and apoptotic cells 
showed greater mean fluorescence intensity (MFI) with 
C2Am-AF750 than viable cells, for both cell lines (Fig. 2c, 
d). Overall, the C2Am-AF750 MFI ratio for dead/viable 
cells (Fig.  2e, f, closed circles) at 24  h after treatment 
was similar for both cell lines (~ 10). Cell staining using 
Annexin-V (Fig. S5) indicated similar levels of apoptotic 
and necrotic cells, as those determined with C2Am, 
albeit the labeling of viable MDA-MB-231 and Colo205 
cells using Annexin-V was greater than that observed 
for C2Am, as reported previously [6]. Incubation of 
18F-C2Am with the cells showed ~ 4-fold greater reten-
tion of activity by MEDI3039-treated cells, in comparison 
with vehicle-treated control cells (see signal-to-back-
ground ratio (SBR) in Fig. 2g, h). The greater retention of 
18F-C2Am by MEDI3039-treated Colo205 cells (Fig. 2h) 
implies that there was greater exposure of PS in the pre-
dominantly apoptotic Colo205 cells as opposed to the 
predominantly necrotic MDA-MB-231 cells (Fig.  2a, b). 
Treatment of the Colo205 cells produced a large number 
of small apoptotic bodies (∼8 μm vs 14 μm diameter for 
intact cells) and failure to fully capture these by centrifu-
gation may have contributed to the variation observed in 
18F-C2Am retention in the cell pellets (Fig. 2h).
Biodistribution of 18F‑C2Am
Biodistribution was assessed in MEDI3039- and vehicle-
treated control mice bearing Colo205 tumors (Fig.  3). 
Two hours following 18F-C2Am administration most 
tissues showed low levels of activity (< 2% IA/g). Tumor 
activity post-treatment was at least ∼  2-fold greater 
than in every other organ with the exception of kidney 
(the main clearance route). Renal retention (∼ 6% IA/g) 
was low and identical in both cohorts. The uptake of 
18F-C2Am was significantly higher (P < 0.05) in tumor, 
spleen and liver tissue following treatment, albeit the 
increase was smaller (~ 2.5 ×) in spleen and liver, com-
pared with tumor (~  5 ×) (Fig.  3). There was increased 
cell death in the spleen (P < 0.001) and liver following 
MEDI3039 treatment, although the increase in the liver 
was not significant (Additional file  1: Fig. S6), which is 
likely due to low-level expression of TRAILR2 in these 
tissues [23]. The blood half-life of 18F-C2Am, calcu-
lated from the analysis of dynamic data obtained from 
ROIs placed in the carotid artery, was 12.4 ± 2.2  min. 
18F-C2Am was stable in plasma for up to 8  h at 37  °C 
(Additional file  1: Fig. S7) and was found to be intact 
in mouse blood in  vivo at 15  min post-administration 
(Additional file 1: Fig. S8A), although by 30 min a lower 
molecular weight metabolite (< 3 kDa) had appeared and 
by 60 min approximately half of the radioactivity present 
was in this metabolite (Additional file 1: Fig. S8C-D). The 
same metabolite also appeared in the urine at 15  min 
and its concentration increased further at 30 and 60 min 
(Additional file 1: Fig. S8B, C-D), suggesting that there is 
some loss of the prosthetic group in vivo.
Dynamic PET imaging of tumor cell death using 18F‑C2Am
Dynamic PET imaging (Fig. 4a, b) confirmed renal excre-
tion as the predominant clearance route for 18F-C2Am. 
Bladder signal could be detected within 5–10  min of 
administration (Fig.  4a, b) and kidney cortical uptake 
peaked (at ~  40% IA/g) within 20–30  min of injection 
(Fig.  4c, d, green line), but was minimal at 2  h post-
administration (~ 3% IA/g; Additional files 2, 3: videos 1 
and 2). Tumor signal (Fig. 4a,b) could be detected within 
15  min of injection, and there was a small component 
(< 10%) of hepatobiliary clearance (Fig.  4c, d, blue line). 
Tumor-to-muscle (T/m) and tumor-to-blood (T/b) ratios 
were 10.7 ± 2.4 and 3.6. ± 0.5, respectively, for MDA-
MB-231 tumors and 6.1 ± 2.1 and 2.4 ± 0.4, respec-
tively, for Colo205 tumors, at 2 h post-administration of 
18F-C2Am. Analysis of individual tumors before and after 
treatment (Fig. 4e) showed significant increases in tumor 
retention (IA/g, %) of 18F-C2Am at 1 h (P < 0.005) and 
2 h (P < 0.05) post-administration, for both models. This 
significant difference (P < 0.05) between pre- and post-
treatment 18F-C2Am tumor uptake was also observed 
using SUV as the contrast metric (Fig.  4f ). The tumor 
cells had been transduced with a viral vector express-
ing firefly luciferase prior to implantation, and both 
tumor models showed a significant decrease in biolumi-
nescence (P < 0.05) post-treatment, where this decrease 
correlated with increased tumor uptake of 18F-C2Am in 
MDA-MB-231 (IA/g, %) and in Colo205 (T/b) tumors 
(Fig.  4g). The levels of 18F-C2Am tumor contrast (SUV 
and  SUVmax; Fig. S9), obtained 1 h post-administration, 
were 0.24 ± 0.14 and 0.66 ± 0.18, respectively. There was 
a dose-dependent response to TRAIL2 agonist therapy 
in treated tumors for both models (Additional file 1: Fig. 
S10).
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Fig. 2 C2Am binds to dead cells in vitro. Flow cytometric analysis of MEDI3039‑treated MDA‑MB‑231 (a) and Colo205 (b) cells shows three 
distinct populations (first and third plots, from left), which were gated based on their levels of  UVA autofluorescence (NADH content) and plasma 
membrane integrity (Sytox R) as: viable (v%), apoptotic (a%) and necrotic (n%) cells. C2Am‑AF750, a near infrared fluorophore‑labeled derivative of 
C2Am labels (second and fourth plots) preferentially bound apoptotic (orange) and necrotic (red) cells, in comparison with viable (green) cells (c, d). 
Plots of C2Am‑AF750 mean fluorescence intensity (MFI) ratios for necrotic/viable, apoptotic/viable and dead/viable MDA‑MB‑231 (e) and Colo205 
(f) cells following treatment with MEDI3039 (mean ± SD, n = 3), error bars lie within the symbols when not shown. MEDI3039‑treated MDA‑MB‑231 
(g) and Colo205 (h) cells were incubated with 18F‑C2Am at different concentrations (1–1000 nM) and the fraction of activity retained in the cell 
pellets (%) after three washes was measured. The signal‑to‑background ratio (SBR, black bars) of treated (grey bars) versus vehicle‑treated (open 
bars, control) cells is also shown
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Only ~  15% of the contrast obtained with 18F-C2Am 
was observed with 18F-iC2Am (Fig.  5). Using unlabeled 
C2Am as a pre-blocking agent, at 10  × higher molar 
dose (1.5  mg/kg), generating a C2Am concentration of 
~  30  nM in the tumor, resulted in a ~  70% decrease of 
18F-C2Am retention in drug-treated tumors (Fig. 6c).
Correlation of 18F‑C2Am with cell death markers
We analyzed several metrics of tumor contrast and 
their correlation with histological markers of tumor cell 
death in both the Colo205 and MDA-MB-231 tumor 
models (Fig.  7). IA/g (%), SUV,  SUV50 and T/b were 
found to best correlate with these cell death markers in 
both tumor models (Fig.  7a), particularly with cleaved 
caspase-3 staining (CC3, open bars; P < 0.05; R > 0.6). 
 SUV90 at 2  h post-probe administration correlated well 
with CC3 staining (Fig. 7a, P < 0.01, R > 0.6) but not with 
TUNEL (P > 0.05). Tumor contrast was also evaluated 
pre- and post-treatment for the same mice and expressed 
as ratios (post/pre-treatment) for IA/g (%), SUV or T/b 
(Fig. 7b). All three contrast metrics showed a good cor-
relation with cleaved caspase-3 staining (CC3, %) in 
both tumor models, both at 1 h (P < 0.005; R > 0.62) and 
2 h post-administration of 18F-C2Am (P < 0.03; R > 0.52). 
The slopes of the best fit lines for each metric, at 1 h or 
2 h post-injection, were not significantly different. Over-
all, for all three metrics, a 20% increase in CC3 positivity 
resulted in a one unit increase in the post/pre-treatment 
tumor contrast. The correlation of 18F-C2Am tumor sig-
nal (expressed as %IA/g, SUV or T/b) post-treatment 
with CC3 positivity was in general better for the Colo205 
model (0.69 < R < 0.86) than for the MDA-MB-231 model 
(0.47 < R < 0.68; Fig. S11).  SUVmax showed a good correla-
tion with CC3 positivity for MDA-MB-231 (R > 0.76) but 
not for Colo205 (R < 0.23; Additional file 1: Fig. S11). The 
correlation of the variation in 18F-C2Am tumor contrast 
with treatment (Additional file 1: Fig. S12) with CC3 pos-
itivity was better when expressed as ΔSUV (R = 0.694) 
than as ΔSUVmax (R = 0.567), 1 h after the injection of 
the contrast agent.
18F‑C2Am signal in vivo and ex vivo versus histology
Next, we compared the percentage of the area occu-
pied by dead cells on histology (CC3, %; Fig.  8a) with 
18F-C2Am uptake in vivo (IA/g, %; Fig. 8b) and with the 
percentage of the area occupied by the 18F-C2Am signal 
in autoradiographs of excised tumor sections obtained 
following completion of the PET studies (Fig.  8c), 2  h 
post-administration of the imaging agent. Low levels of 
tumor cell death (CC3 < ∼10%, Fig.  8a) generated low 
levels of 18F-C2Am retention, as detected by PET in vivo 
(IA/g, ~  0.7%, Fig.  8b) and autoradiography ex  vivo 
(~ 6%; Fig. 8c). Tumor PET and autoradiography signals 
increased significantly (IA/g, ~  1.7%, P < 0.05) with the 
extent of tumor cell death commonly generated by con-
ventional therapies (CC3 > ~  20%,) [24]. 18F-C2Am sig-
nal in tumors post-treatment was heterogeneous in both 
models, as shown in multi-slice images from the tumors 
Fig. 3 Biodistribution profile of 18F‑C2Am, 2 h post‑administration. 
Mice bearing Colo205 tumors were treated with MEDI3039 (closed 
bars; 0.4 mg/kg, i.v., 24 h) or vehicle (open bars). 18F‑C2Am was 
injected (1 MBq, i.v.) and tissues collected post‑mortem 2 h following 
administration. Fraction of injected activity per gram of tissue (IA/g, 
%) (mean ± SEM, n = 5 per treatment group). Two‑tailed, t test, 
unequal variance. *P < 0.05
Fig. 4 PET images of 18F‑C2Am in tumor‑bearing mice, pre‑ and post‑treatment. Maximum intensity projections of the PET signal in sagittal 
sections of representative mice, bearing MDA‑MB‑231 (a) and Colo205 (b) tumors. Projections are shown from immediately before (0) and up to 
120 min after injection of 18F‑C2Am. Signal is shown as injected activity per gram of tissue (IA/g, %) and overlaid on a CT‑derived skeleton mask. 
White arrows indicate tumor location. Time–activity (IA/g, %) curves for the indicated tissues in treated (MEDI3039, 0.4 mg/kg, 24 h) MDA‑MB‑231 (c) 
and Colo205 (d) tumor‑bearing mice. Also shown are tumor‑to‑blood (T/b) and tumor‑to‑muscle (T/m) ratios for both tumor models. e, f Pairwise 
analysis of PET signal pre‑ and 1 h (first and third columns) or 2 h (second and fourth columns) post‑treatment, expressed as IA/g (%) (e) or SUV (f). 
Pairwise analysis (g) of tumor bioluminescence pre‑ and post‑treatment (first and third plots) and correlation analysis (Pearson) of tumor PET signal 
with the reduction in BLI signal (second and fourth plots), 1 h after 18F‑C2Am administration. Data (c, d) is mean ± SEM, n = 5−6 per treatment 
group. Black and red symbols (e, g) correspond to MEDI3039 treatment at 0.4 or 0.1 mg/kg (for 24 h), respectively. e, g Two‑tailed, pairwise t test, 
unequal variance. *P < 0.05, **P < 0.01
(See figure on next page.)
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Fig. 5 Reduced tumor uptake of (inactive) 18F‑iC2Am versus (active) 18F‑C2Am in MEDI3039‑treated mice (0.4 mg/kg, 24 h, i.v.) bearing Colo205 
tumors. Red lined triangles (18F‑C2Am); black lined squares (18F‑iC2Am)
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Fig. 6 Effect of pre‑blocking of PS using (× 10) molar excess of unlabeled C2Am on 18F‑C2Am tumor contrast in MEDI3039‑treated mice (0.4 mg/
kg, 24 h, i.v.) bearing MDA‑MB‑231 tumors. Red lined triangles (18F‑C2Am; no pre‑blocking); black lined squares (18F‑C2Am; 10x pre‑blocking with 
C2Am)
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(Additional file 1: Fig. S13), reflecting the heterogeneous 
distribution of cell death observed on histology (Fig. 8a).
18F‑C2Am dosimetry
A dosimetry analysis was used to estimate the corre-
sponding human dosimetry (Additional file 1: Table 1) 
using the interspecies scaling model proposed by 
Maina et  al. [25] in order to examine the feasibility of 
translating 18F-C2Am into the clinic. 18F-C2Am cleared 
from the mice rapidly with 27.3 ± 6.1% and 113.9 ± 18% 
of the injected radioactivity collecting in the blad-
der at one and 2  h after injection, respectively (n = 6). 
The highest uptake was observed in the bladder, kid-
neys and liver. The estimated human-scaled effective 
dose was 12.5 ± 5.7 μSv/MBq (human effective dose 
estimate, in accordance with publication 103 of the 
Fig. 7 Pearson correlation analysis of tumor PET signal with histological markers of cell death. a Pearson P (left) and R (right) correlation values 
for tumor signal, expressed as different contrast metrics, 1 h and 2 h post‑administration of 18F‑C2Am, with cell death markers (CC3, open bars, or 
TUNEL, closed bars) estimated from two sections (200 µm apart) from the same tumors, from both Colo205 and MDA‑MB‑231 models. (b) Pearson 
correlation analysis of tumor contrast, expressed as IA/g, % (left), SUV (middle) and T/b ratio (right), 1 h (top row) or 2 h (lower row) after 18F‑C2Am 
administration, with tumor cell death (CC3, %). Tumor contrast is expressed as the signal ratio, post/pre‑treatment. Pooled data (a, b) from Colo205 
(n = 9, red symbols) and MDA‑MB‑231 (n = 9, blue symbols) tumor‑bearing mice, treated with MEDI3039 (0.1 or 0.4 mg/kg, 24 h, i.v., filled symbols), 
5FU (Colo205, 100 mg/kg, i.p., 24 h, open red symbols) or doxorubicin (MDA‑MB‑231, 100 mg/kg, i.p., 24 h, open blue symbols). Two‑tailed, 
Pearson P and R values are shown (a). CC3 cleaved caspase 3, TUNEL terminal deoxynucleotidyl transferase‑mediated dUTP nick‑end labeling. T/b 
tumor‑to‑blood ratio, Tx treatment
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International Commission on the Radiological Protec-
tion, ICRP [26]).
Discussion
Imaging cell death can provide an indication of disease 
prognosis [27] and in cancer can be used to detect treat-
ment response [3, 28]. Imaging agents that target vari-
ous cell death-related events, such as cleaved caspase-3 
(CC3) [24], changes in mitochondrial membrane poten-
tial [29], alterations in membrane permeability [30] and 
exposure of PS [31] and phosphatidylethanolamine (PE) 
[32] have been described [28], some of which have trans-
lated to the clinic [33]. However, the success of these 
agents has so far been limited. A CC3 targeted agent, 
18F-ICMT-11, showed a lack of sensitivity for detect-
ing cell death in breast and lung cancer patients treated 
with chemotherapy [34] and 18F-ML-10, an agent that 
detects changes in membrane permeability during apop-
tosis, failed to detect response to chemotherapy in a pre-
clinical model of breast cancer [35]. Exposure of PS [31] 
and PE [32], which are externalized on the outer leaflet 
of the plasma membrane during apoptosis, or become 
accessible following plasma membrane disruption dur-
ing necrosis, are attractive imaging targets since they 
provide a sustained and abundant target [14] that can 
give good image contrast [36]. 99mTc-Annexin V, which 
binds PS, has translated to the clinic; however, it showed 
poor pharmacokinetics and non-specific binding [33]. 
Exposure of PE by dying cells has been exploited in the 
development of duramycin, a 19 amino acid tetracyclic 
peptide (~ 2 kDa), as a cell death imaging agent [37, 38]. 
However, despite its smaller size the clearance profile 
and contrast generated by 99mTc-duramycin was similar 
to that observed here with 18F-C2Am. Following treat-
ment of Colo205 tumors with a TRAILR2 agonist, the 
increase in tumor-to-muscle (T/m) contrast generated 
by 99mTc-duramycin was 30.8 ± 1.9 ⨉ [37]. However, 
when corrected for non-specific retention using a con-
trol treatment antibody [37], the T/m was 6.9 ± 1.5×, 
which is similar to that observed here with 18F-C2Am 
Fig. 8 Correlation of 18F‑C2A signal with immunohistochemical markers of cell death for representative MDA‑MB‑231 and Colo205 tumors. a 
Cleaved caspase‑3 (CC3). Tumor section positive CC3 pixel count values (%) are shown. b Maximum intensity projection (MIP) of PET signal (IA/g, 
%). c Autoradiography of tumor sections acquired immediately after imaging (% of area with signal). Tumors were collected from different mice, 
bearing either Colo205 or MDA‑MB‑231, 2 h following administration of 18F‑C2Am. MEDI3039 (MEDI) used at 0.4 mg/kg, i.v., for 24 h. 5FU and 
Doxorubicin (Dox) were both used at 100 mg/kg, i.p., for 24 h. UT untreated tumors
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(6.1 ± 2.1×). The retention of 18F-iC2Am, which is non-
specific, was ~15%. More importantly, for clinical transla-
tion, 18F-C2Am showed comparable blood half-life (t1/2: 
12.4 ± 2.2  min) to that reported recently for the small 
PET agent 68Ga-duramycin (t1/2: 17.3 ± 4.12  min) [39], 
but longer than that observed previously for the SPECT 
agent 99mTc-duramycin (t1/2: 4.1 ± 0.3  min) [40]. Cell 
death-dependent contrast was obtained earlier using 
18F-C2Am, at 2 h following agent administration, as com-
pared to 4 h for 99mTc-duramycin.
18F-C2Am also cleared more quickly than the γ-emitter 
labeled C2Am derivatives described previously (99mTc-
C2Am, t1/2: 582 ± 6 min; 111In-C2Am,  t1/2: 480 ± 48 min) 
[15] and gave higher T/m ratios (∼ 6–10 ×) as compared 
to 99mTc-C2Am (~  4.3  ×) and 111In-C2Am (~  2.2  ×), 
albeit with different tumor models (EL4 and Colo205) 
and treatment (chemotherapy) [15]. The C2Am fragment 
(< 3 kDa) detected in serum and urine, within 30 min of 
administration, is likely the result of proteolytic cleavage 
in the liver and/or kidney, which could contribute to this 
rapid clearance. The mean  SUVmax for 18F-C2Am at 1 h 
post-administration (0.66 ± 0.18) was greater than that 
reported previously for a much larger 18F-labeled C2A 
derivative (18F-GST-C2A; 80  kDa;  SUVmax = 0.47 ± 0.28) 
[10]. Moreover, no inactive C2A controls were performed 
in this previous study, suggesting that a substantial part 
of the tumor signal may have been caused by non-specific 
retention [10]. 18F-C2Am showed greater T/m contrast 
(two- to threefold) for identical levels of cell death and 
lower (2–10  ×) non-specific retention in other tissues 
post-treatment when compared to 18F-ICMT-11 [24], 
18F-ML-10 [35], 99mTc-Duramycin [36], and 18F-Annexin 
V [41].
Pre-blocking PS using unlabeled C2Am at tenfold 
greater molar dose than 18F-C2Am resulted in a ~  70% 
reduction in tumor retention of 18F-C2Am. This reduc-
tion was much greater than expected given the high lev-
els of PS predicted to be exposed by dying cells in these 
tumors (~ 30 μM), based on cell treatment experiments 
in vitro [14], and suggests that the PS accessible to C2Am 
in vivo is much less than this.
The levels of tumor cell death observed in the clinic can 
vary widely, from a few percent pre-treatment to 5–16% 
apoptosis following neoadjuvant treatment in breast can-
cer [42, 43]. 18F-C2Am detects both apoptosis and necro-
sis and therefore should be more sensitive than those 
agents that detect apoptosis alone, such as 18F-ML-10 
[35]. Moreover, C2Am is also capable of binding PE [44], 
which like PS, is also externalized to the surface of dying 
cells.
The contrast observed here, where SUV doubled within 
an hour of 18F-C2Am injection following an increase in 
cell death from 8 to 20%, suggests that this agent should 
detect the expected levels of tumor cell death in the 
clinic. Analysis of 18F-C2Am signal heterogeneity, for 
example using Minkowski functionals, which we have 
used previously to analyze the heterogeneous distribu-
tion of a gadolinium chelate-conjugated derivative of 
C2A in magnetic resonance images [45], could further 
enhance the sensitivity of the agent for detecting treat-
ment response.
The estimated human mean effective dose with 
18F-C2Am is 12.5 ± 5.7 μSv/MBq, which was higher than 
that estimated for the SPECT tracer 99mTc-duramycin 
(3.19 ± 2.16 μSv/MBq) [40], but similar to that observed 
recently for a small molecule PET tracer (18F-PSMA-11; 
12.8 ± 0.6  μSv/MBq) [46], and for a biologic (99mTc-
Annexin-V; 9.7 ± 1.0  μSv/MBq) [47]. The total esti-
mated effective human dose of 18F-C2Am equates to 
5.6 ± 2.6 mSv (450 MBq injected), which is less than the 
PET element of a  [18F]FDG PET/CT scan, 9.0 ± 1.6 mSv 
[48].
In conclusion, we have demonstrated 18F-C2Am as a 
PET agent for imaging cell death in vivo that showed fast 
renal clearance, good tumor contrast post-treatment and 
acceptable dosimetry. 18F-C2Am has the potential to be 
used in the clinic to assess early treatment response in 
tumors, such as breast, prostate, lung and colorectal.
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